CAV1 and Alzheimer disease: In summary, upregulating CAV-1 expression, reducing GSK-3β activity, and inhibiting excessive abnormal phosphorylation of Tau protein may be one of the molecular mechanisms of RSBFL for the prevention and treatment of AD.